drugset / Trial / NCT01967238

An Open Label Study of IgG Fc Glycan Composition in Human Immunity

NCT01967238

Phase 0 Terminated 129 enrolled Rockefeller University
Non-randomizedSingle-groupOpen-labelBasic science

Summary

In order to produce better more effective vaccines, it is important to understand the particulars of why individuals have an effective or ineffective immune response to vaccination. We are going to examine specific aspects of the antibody (IgG Fc glycan) made by healthy volunteers who receive different vaccines or who have a viral infection to understand the nature of an effective (or less effective) vaccine response. The results of this research could be used to develop adjuvants to increase/ improve vaccine response.

Timeline

Start
2013-03
Primary completion
2023-03
Completion
2023-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Influenza Virus Vaccine Vaccine Intramuscular
Comparator Pneumococcal Vaccine Intramuscular
Comparator meningococcal Vaccine Intramuscular

Indications

No indication recorded.